What significant change did the Medical Device User Fee and Modernization Act of 2002 enact?

Prepare for the Regulatory Affairs Certification (RAC) exam with comprehensive quiz tools. Practice with flashcards and multiple choice questions, complete with hints and detailed explanations. Equip yourself with the knowledge to ace your certification exam!

Multiple Choice

What significant change did the Medical Device User Fee and Modernization Act of 2002 enact?

The key change introduced by this act is the start of user fees for premarket device reviews. Before this, FDA funding for reviewing medical device submissions came strictly from Congressional appropriations. The act created a fee structure for determining pay-in filings such as PMA and 510(k) submissions, giving FDA resources and a commitment to meet specific review timelines in exchange for the fees. This shift aimed to speed up and modernize the device review process by providing a more predictable funding stream and clearer performance goals. The other options don’t capture that central shift. The Office of Combination Products was set up later to coordinate among different centers, not as the defining feature of this act. Renewal of a drug user fee program and changes to labeling relate to other regulatory programs or different legislation.

The key change introduced by this act is the start of user fees for premarket device reviews. Before this, FDA funding for reviewing medical device submissions came strictly from Congressional appropriations. The act created a fee structure for determining pay-in filings such as PMA and 510(k) submissions, giving FDA resources and a commitment to meet specific review timelines in exchange for the fees. This shift aimed to speed up and modernize the device review process by providing a more predictable funding stream and clearer performance goals.

The other options don’t capture that central shift. The Office of Combination Products was set up later to coordinate among different centers, not as the defining feature of this act. Renewal of a drug user fee program and changes to labeling relate to other regulatory programs or different legislation.

More practice questions